Trial Profile

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KFA-115 (Primary) ; Tislelizumab (Primary)
Indications Anal cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Malignant thymoma; Mesothelioma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Skin cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

Most Recent Events

05 Mar 2025 Planned End Date changed from 20 Feb 2026 to 1 Sep 2027.
05 Mar 2025 Planned primary completion date changed from 20 Feb 2026 to 1 Sep 2027.
21 Mar 2024 Planned number of patients changed from 220 to 180.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com